

List of Publications by Year
in descending order

Source: <https://exaly.com/author-pdf/11077031/publications.pdf>

Version: 2024-02-01

52
papers

22,812
citations

117625

34
h-index

149698

56
g-index

57
all docs

57
docs citations

57
times ranked

18632
citing authors

#	ARTICLE	IF	CITATIONS
1	The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure. New England Journal of Medicine, 2005, 352, 1539-1549.	27.0	5,656
2	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.2	4,537
3	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2022, 43, 561-632.	2.2	2,169
4	Impact of Formal Continuing Medical Education. JAMA - Journal of the American Medical Association, 1999, 282, 867.	7.4	1,987
5	The perindopril in elderly people with chronic heart failure (PEP-CHF) study. European Heart Journal, 2006, 27, 2338-2345.	2.2	1,280
6	beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ: British Medical Journal, 1999, 318, 1730-1737.	2.3	1,211
7	Understanding Patients'™ Adherence-Related Beliefs about Medicines Prescribed for Long-Term Conditions: A Meta-Analytic Review of the Necessity-Concerns Framework. PLoS ONE, 2013, 8, e80633.	2.5	799
8	Composite Outcomes in Randomized Trials. JAMA - Journal of the American Medical Association, 2003, 289, 2554.	7.4	627
9	Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CARDiac RESynchronization-Heart Failure (CARE-HF) trial extension phase]. European Heart Journal, 2006, 27, 1928-1932.	2.2	586
10	Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A meta-analysis. British Journal of Psychiatry, 2002, 180, 396-404.	2.8	510
11	2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Journal of Cardio-thoracic Surgery, 2021, 60, 727-800.	1.4	344
12	Continuing education meetings and workshops: effects on professional practice and health care outcomes. , 2001, , CD003030.		262
13	Effect of Cardiac Resynchronization on the Incidence of Atrial Fibrillation in Patients With Severe Heart Failure. Circulation, 2006, 114, 18-25.	1.6	225
14	Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a subanalysis of the CARE-HF trial. European Journal of Heart Failure, 2009, 11, 699-705.	7.1	202
15	Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response. Journal of the American College of Cardiology, 2008, 52, 438-445.	2.8	186
16	Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. European Journal of Heart Failure, 2009, 11, 480-488.	7.1	167
17	2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention, 2022, 17, e1126-e1196.	3.2	161
18	The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. European Heart Journal, 2006, 28, 42-51.	2.2	159

#	ARTICLE	IF	CITATIONS
19	Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterized by dyssynchrony: a pre-defined analysis from the CARE-HF trial. European Heart Journal, 2007, 28, 1827-1834.	2.2	147
20	Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. European Heart Journal, 2007, 28, 1592-1597.	2.2	144
21	The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. European Heart Journal, 2008, 30, 782-788.	2.2	132
22	Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. European Heart Journal, 2005, 26, 2681-2688.	2.2	121
23	Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization Heart Failure (CARE-HF) trial. European Journal of Heart Failure, 2012, 14, 628-634.	7.1	121
24	Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.8	113
25	Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the Cardiac Resynchronisation-Heart Failure (CARE-HF) study. American Heart Journal, 2009, 157, 457-466.	2.7	96
26	Prevalence of ECG abnormalities in an international survey of patients with suspected or confirmed heart failure at death or discharge. European Journal of Heart Failure, 2007, 9, 491-501.	7.1	91
27	The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 172-185.	3.2	88
28	Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records. Health Technology Assessment, 2016, 20, 1-176.	2.8	82
29	Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-HF study. European Journal of Heart Failure, 2012, 14, 487-494.	7.1	61
30	Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2009, 53, 608-611.	2.8	58
31	Composite and surrogate outcomes in randomised controlled trials. BMJ: British Medical Journal, 2007, 334, 756-757.	2.3	51
32	How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?. BMJ: British Medical Journal, 2005, 331, 836-838.	2.3	43
33	The Limit of Plausibility for Predictors of Response: Application to Biventricular Pacing. JACC: Cardiovascular Imaging, 2012, 5, 1046-1065.	5.3	42
34	Weighing the pros and cons for composite outcomes in clinical trials. Journal of Clinical Epidemiology, 2007, 60, 658-659.	5.0	41
35	Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. European Heart Journal, 2009, 30, 2109-2116.	2.2	36
36	Predictors of Mortality From Pump Failure and Sudden Cardiac Death in Patients With Systolic Heart Failure and Left Ventricular Dyssynchrony: Results of the CARE-HF Trial. Journal of Cardiac Failure, 2008, 14, 670-675.	1.7	34

#	ARTICLE	IF	CITATIONS
37	Clinical trials update from the American Heart Association 2006: OAT, SALT 1 and 2, MAGIC, ABCD, PABA-CHF, IMPROVE-CHF, and percutaneous mitral annuloplasty. European Journal of Heart Failure, 2007, 9, 92-97.	7.1	33
38	The use of interim data and Data Monitoring Committee recommendations in randomized controlled trial reports: frequency, implications and potential sources of bias. BMC Medical Research Methodology, 2008, 8, 12.	3.1	33
39	On the pooling and subgrouping of data from percutaneous coronary intervention versus coronary artery bypass grafting trials: a call to circumspection. European Journal of Cardio-thoracic Surgery, 2018, 53, 915-918.	1.4	17
40	Prevalence and inter-relationship of different Doppler measures of dyssynchrony in patients with heart failure and prolonged QRS: a report from CARE-HF. Cardiovascular Ultrasound, 2009, 7, 1.	1.6	12
41	Commentary: The left main controversy: Is this a real subgroup requiring custom clinical recommendations?. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 108-110.	0.8	9
42	PROactive study. Lancet, The, 2006, 367, 24-25.	13.7	7
43	Beliefs of Health Care Providers, Lay Health Care Providers and Lay Persons in Nigeria Regarding Hypertension. A Systematic Mixed Studies Review. PLoS ONE, 2016, 11, e0154287.	2.5	7
44	Clinical trials update from the American College of Cardiology Meeting 2011: STICH, NorthStar, TARGET, and EVEREST II. European Journal of Heart Failure, 2011, 13, 805-808.	7.1	6
45	Transcatheter versus surgical aortic valve replacement: what does the latest evidence tell us?. European Journal of Cardio-thoracic Surgery, 2019, 56, 7-9.	1.4	6
46	Physiotherapy trials for the 21st century – time to raise the bar?. Journal of the Royal Society of Medicine, 2011, 104, 437-441.	2.0	5
47	Can cardiac-resynchronization therapy reduce mortality in patients suffering from advanced chronic heart failure?. Nature Clinical Practice Cardiovascular Medicine, 2004, 1, 10-11.	3.3	3
48	Composite outcomes – final comment for now. Journal of Clinical Epidemiology, 2007, 60, 662.	5.0	3
49	The conundrum of the treatment for left main coronary disease. European Heart Journal, 2020, 41, 3236-3238.	2.2	3
50	Answering important questions reliably-GISSI Heart Failure, a factorially designed trial with composite (co)primary outcome measures. European Journal of Heart Failure, 2004, 6, 531-533.	7.1	2
51	The review by Weinmann and colleagues. Psychopharmacology, 2008, 199, 131-132.	3.1	2
52	The path for medical associations to sponsor trustworthy guidelines: is it feasible?. Journal of the Royal Society of Medicine, 2022, 115, 252-256.	2.0	2